Application Note: Efficient Gene Editing of iPSCs
Induced pluripotent stem cells (iPSCs) hold immense promise for regenerative medicine, offering a versatile platform for developing personalized cell therapies. However, efficiently editing these cells while maintaining cell health and functional integrity remains a significant challenge to cell therapy manufacturers. To address this, CellFE has developed a non-viral workflow that enables high-efficiency mRNA delivery into iPSCs using the microfluidic-based Ryva™ mechanoporation platform, ensuring high cell viability, delivery efficiency, and rapid recovery.
The Efficient Gene Editing of iPSCs application note delves into the advantages of using iPSCs for both autologous and allogeneic therapies, highlighting how CellFE’s delivery technology and optimized workflow can streamline manufacturing processes and enhance therapeutic outcomes.
Why CellFE iPSC Gene Editing Stands Out
The CellFE workflow and Ryva™ mechanoporation system offers several advantages that set it apart from conventional delivery methods:
- Non-Viral Approach: Eliminate the potential risks associated with alternative delivery approaches, ensuring a safer and more controlled process.
- Enhanced Efficiency: Achieve consistent, high-level mRNA delivery, critical for both research and clinical applications.
- Preserved Cell Viability: Maintain high cell viability, which is essential for downstream applications in cell therapy manufacturing.
- Versatility: Adaptable for use with even the largest payload types, making it a comprehensive solution for a variety of therapeutic needs.
Connect with us on LinkedIn for more updates as we continue to innovate and push the boundaries of what’s possible in gene editing and cell therapy.
Interested in learning more about our gene editing workflows and technology? Contact Us.